Immunohistochemical analysis of NANOG expression and epithelial-mesenchymal transition in pulmonary sarcomatoid carcinoma

Pulmonary sarcomatoid carcinomas (PSCs) are defined as a group of poorly differentiated non-small cell lung cancers that demonstrate sarcoma-like differentiation. The mechanism of mesenchymal differentiation in PSC is epithelial-mesenchymal transition (EMT). The expression of homeobox protein NANOG...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2017-05, Vol.13 (5), p.3695-3702
Main Authors: Tamaki, Takeshi, Shimizu, Toshiki, Niki, Maiko, Shimizu, Michiomi, Nishizawa, Tohru, Nomura, Shosaku
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c450t-1bd817da55caf8fd566b47aee69d8c88a8af4b2467b0d6102bf6667439675ff53
cites cdi_FETCH-LOGICAL-c450t-1bd817da55caf8fd566b47aee69d8c88a8af4b2467b0d6102bf6667439675ff53
container_end_page 3702
container_issue 5
container_start_page 3695
container_title Oncology letters
container_volume 13
creator Tamaki, Takeshi
Shimizu, Toshiki
Niki, Maiko
Shimizu, Michiomi
Nishizawa, Tohru
Nomura, Shosaku
description Pulmonary sarcomatoid carcinomas (PSCs) are defined as a group of poorly differentiated non-small cell lung cancers that demonstrate sarcoma-like differentiation. The mechanism of mesenchymal differentiation in PSC is epithelial-mesenchymal transition (EMT). The expression of homeobox protein NANOG (NANOG), which regulates the pluripotency of embryonic stem cells, is associated with the EMT process. Therefore, the present study aimed to assess the expression level of NANOG and the status of the EMT process in PSC. The data of patients with PSC were retrospectively reviewed and immunohistochemical analyses were performed on patient samples to examine the expression of NANOG and EMT-associated proteins. The comparator group included randomly selected patients with matched clinicopathological characteristics who had pulmonary adenocarcinoma (PA). In the present study, 12 patients with PSC (4 females and 8 males) were enrolled; their median age was 65 years (range, 36-79 years), and the number of patients with stage IB, IIB, IIIA, IIIB and IV disease were 1, 1, 1, 1 and 8, respectively. The immunoreactive score (IRS) for E-cadherin was significantly lower in the PSC group compared with the PA group (P
doi_str_mv 10.3892/ol.2017.5864
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5431690</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1901310901</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-1bd817da55caf8fd566b47aee69d8c88a8af4b2467b0d6102bf6667439675ff53</originalsourceid><addsrcrecordid>eNpVUU1LxDAQDaKorHvzLD16sGvSNml6EZZF14XFveg5pGliI_moTSvuvzdFXXQO88G8efPgAXCJ4CKnVXbrzSKDqFxgSoojcI7KKksRpNnxoS-LMzAP4Q3GwARRSk7BWUZxVsWbc7DfWDs63-oweNFKqwU3CXfc7IMOiVfJ0_Jpt07kZ9fLELR3cdkkstNDK43mJrUySCfavY13Q89d0MOE0i7pRmO94_0-CbwX3vLB6yYRsdcuThfgRHET5PynzsDLw_3z6jHd7tab1XKbigLDIUV1Q1HZcIwFV1Q1mJC6KLmUpGqooJRTroo6K0hZw4YgmNWKEFIWeUVKrBTOZ-Dum7cbaysbIV2UaVjXaxu1Mc81-79xumWv_oPhIkekgpHg-oeg9--jDAOzOghpDHfSj4GhCqIcwSnPwM03VPQ-hF6qwxsE2WQY84ZNhrHJsAi_-ivtAP61J_8CVq6Vkw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901310901</pqid></control><display><type>article</type><title>Immunohistochemical analysis of NANOG expression and epithelial-mesenchymal transition in pulmonary sarcomatoid carcinoma</title><source>PubMed Central</source><creator>Tamaki, Takeshi ; Shimizu, Toshiki ; Niki, Maiko ; Shimizu, Michiomi ; Nishizawa, Tohru ; Nomura, Shosaku</creator><creatorcontrib>Tamaki, Takeshi ; Shimizu, Toshiki ; Niki, Maiko ; Shimizu, Michiomi ; Nishizawa, Tohru ; Nomura, Shosaku</creatorcontrib><description>Pulmonary sarcomatoid carcinomas (PSCs) are defined as a group of poorly differentiated non-small cell lung cancers that demonstrate sarcoma-like differentiation. The mechanism of mesenchymal differentiation in PSC is epithelial-mesenchymal transition (EMT). The expression of homeobox protein NANOG (NANOG), which regulates the pluripotency of embryonic stem cells, is associated with the EMT process. Therefore, the present study aimed to assess the expression level of NANOG and the status of the EMT process in PSC. The data of patients with PSC were retrospectively reviewed and immunohistochemical analyses were performed on patient samples to examine the expression of NANOG and EMT-associated proteins. The comparator group included randomly selected patients with matched clinicopathological characteristics who had pulmonary adenocarcinoma (PA). In the present study, 12 patients with PSC (4 females and 8 males) were enrolled; their median age was 65 years (range, 36-79 years), and the number of patients with stage IB, IIB, IIIA, IIIB and IV disease were 1, 1, 1, 1 and 8, respectively. The immunoreactive score (IRS) for E-cadherin was significantly lower in the PSC group compared with the PA group (P&lt;0.0001), whereas the IRS for vimentin was significantly higher in the PSC group compared with the PA group (P&lt;0.0001). However, the IRS for NANOG was significantly decreased in the PSC group compared with the PA group (P&lt;0.0001), which suggests that NANOG does not serve an essential role in EMT in PSC. In addition, the overall survival of patients with PSC was significantly lower compared with that of patients with PA (median survival time, 7.0 vs. 35.6 months, respectively; P=0.0256). However, no significant difference was observed in the OS of patients who expressed low compared with high levels of NANOG (P=0.4416). In conclusion, it was clearly demonstrated that cytoplasmic NANOG expression was significantly lower in PSC compared with PA, and that the EMT process in PSC was accelerated, compared with that in PA.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2017.5864</identifier><identifier>PMID: 28529586</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><ispartof>Oncology letters, 2017-05, Vol.13 (5), p.3695-3702</ispartof><rights>Copyright © 2017, Spandidos Publications 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-1bd817da55caf8fd566b47aee69d8c88a8af4b2467b0d6102bf6667439675ff53</citedby><cites>FETCH-LOGICAL-c450t-1bd817da55caf8fd566b47aee69d8c88a8af4b2467b0d6102bf6667439675ff53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431690/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431690/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28529586$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tamaki, Takeshi</creatorcontrib><creatorcontrib>Shimizu, Toshiki</creatorcontrib><creatorcontrib>Niki, Maiko</creatorcontrib><creatorcontrib>Shimizu, Michiomi</creatorcontrib><creatorcontrib>Nishizawa, Tohru</creatorcontrib><creatorcontrib>Nomura, Shosaku</creatorcontrib><title>Immunohistochemical analysis of NANOG expression and epithelial-mesenchymal transition in pulmonary sarcomatoid carcinoma</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Pulmonary sarcomatoid carcinomas (PSCs) are defined as a group of poorly differentiated non-small cell lung cancers that demonstrate sarcoma-like differentiation. The mechanism of mesenchymal differentiation in PSC is epithelial-mesenchymal transition (EMT). The expression of homeobox protein NANOG (NANOG), which regulates the pluripotency of embryonic stem cells, is associated with the EMT process. Therefore, the present study aimed to assess the expression level of NANOG and the status of the EMT process in PSC. The data of patients with PSC were retrospectively reviewed and immunohistochemical analyses were performed on patient samples to examine the expression of NANOG and EMT-associated proteins. The comparator group included randomly selected patients with matched clinicopathological characteristics who had pulmonary adenocarcinoma (PA). In the present study, 12 patients with PSC (4 females and 8 males) were enrolled; their median age was 65 years (range, 36-79 years), and the number of patients with stage IB, IIB, IIIA, IIIB and IV disease were 1, 1, 1, 1 and 8, respectively. The immunoreactive score (IRS) for E-cadherin was significantly lower in the PSC group compared with the PA group (P&lt;0.0001), whereas the IRS for vimentin was significantly higher in the PSC group compared with the PA group (P&lt;0.0001). However, the IRS for NANOG was significantly decreased in the PSC group compared with the PA group (P&lt;0.0001), which suggests that NANOG does not serve an essential role in EMT in PSC. In addition, the overall survival of patients with PSC was significantly lower compared with that of patients with PA (median survival time, 7.0 vs. 35.6 months, respectively; P=0.0256). However, no significant difference was observed in the OS of patients who expressed low compared with high levels of NANOG (P=0.4416). In conclusion, it was clearly demonstrated that cytoplasmic NANOG expression was significantly lower in PSC compared with PA, and that the EMT process in PSC was accelerated, compared with that in PA.</description><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVUU1LxDAQDaKorHvzLD16sGvSNml6EZZF14XFveg5pGliI_moTSvuvzdFXXQO88G8efPgAXCJ4CKnVXbrzSKDqFxgSoojcI7KKksRpNnxoS-LMzAP4Q3GwARRSk7BWUZxVsWbc7DfWDs63-oweNFKqwU3CXfc7IMOiVfJ0_Jpt07kZ9fLELR3cdkkstNDK43mJrUySCfavY13Q89d0MOE0i7pRmO94_0-CbwX3vLB6yYRsdcuThfgRHET5PynzsDLw_3z6jHd7tab1XKbigLDIUV1Q1HZcIwFV1Q1mJC6KLmUpGqooJRTroo6K0hZw4YgmNWKEFIWeUVKrBTOZ-Dum7cbaysbIV2UaVjXaxu1Mc81-79xumWv_oPhIkekgpHg-oeg9--jDAOzOghpDHfSj4GhCqIcwSnPwM03VPQ-hF6qwxsE2WQY84ZNhrHJsAi_-ivtAP61J_8CVq6Vkw</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Tamaki, Takeshi</creator><creator>Shimizu, Toshiki</creator><creator>Niki, Maiko</creator><creator>Shimizu, Michiomi</creator><creator>Nishizawa, Tohru</creator><creator>Nomura, Shosaku</creator><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170501</creationdate><title>Immunohistochemical analysis of NANOG expression and epithelial-mesenchymal transition in pulmonary sarcomatoid carcinoma</title><author>Tamaki, Takeshi ; Shimizu, Toshiki ; Niki, Maiko ; Shimizu, Michiomi ; Nishizawa, Tohru ; Nomura, Shosaku</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-1bd817da55caf8fd566b47aee69d8c88a8af4b2467b0d6102bf6667439675ff53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Tamaki, Takeshi</creatorcontrib><creatorcontrib>Shimizu, Toshiki</creatorcontrib><creatorcontrib>Niki, Maiko</creatorcontrib><creatorcontrib>Shimizu, Michiomi</creatorcontrib><creatorcontrib>Nishizawa, Tohru</creatorcontrib><creatorcontrib>Nomura, Shosaku</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tamaki, Takeshi</au><au>Shimizu, Toshiki</au><au>Niki, Maiko</au><au>Shimizu, Michiomi</au><au>Nishizawa, Tohru</au><au>Nomura, Shosaku</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunohistochemical analysis of NANOG expression and epithelial-mesenchymal transition in pulmonary sarcomatoid carcinoma</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>13</volume><issue>5</issue><spage>3695</spage><epage>3702</epage><pages>3695-3702</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Pulmonary sarcomatoid carcinomas (PSCs) are defined as a group of poorly differentiated non-small cell lung cancers that demonstrate sarcoma-like differentiation. The mechanism of mesenchymal differentiation in PSC is epithelial-mesenchymal transition (EMT). The expression of homeobox protein NANOG (NANOG), which regulates the pluripotency of embryonic stem cells, is associated with the EMT process. Therefore, the present study aimed to assess the expression level of NANOG and the status of the EMT process in PSC. The data of patients with PSC were retrospectively reviewed and immunohistochemical analyses were performed on patient samples to examine the expression of NANOG and EMT-associated proteins. The comparator group included randomly selected patients with matched clinicopathological characteristics who had pulmonary adenocarcinoma (PA). In the present study, 12 patients with PSC (4 females and 8 males) were enrolled; their median age was 65 years (range, 36-79 years), and the number of patients with stage IB, IIB, IIIA, IIIB and IV disease were 1, 1, 1, 1 and 8, respectively. The immunoreactive score (IRS) for E-cadherin was significantly lower in the PSC group compared with the PA group (P&lt;0.0001), whereas the IRS for vimentin was significantly higher in the PSC group compared with the PA group (P&lt;0.0001). However, the IRS for NANOG was significantly decreased in the PSC group compared with the PA group (P&lt;0.0001), which suggests that NANOG does not serve an essential role in EMT in PSC. In addition, the overall survival of patients with PSC was significantly lower compared with that of patients with PA (median survival time, 7.0 vs. 35.6 months, respectively; P=0.0256). However, no significant difference was observed in the OS of patients who expressed low compared with high levels of NANOG (P=0.4416). In conclusion, it was clearly demonstrated that cytoplasmic NANOG expression was significantly lower in PSC compared with PA, and that the EMT process in PSC was accelerated, compared with that in PA.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>28529586</pmid><doi>10.3892/ol.2017.5864</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1792-1074
ispartof Oncology letters, 2017-05, Vol.13 (5), p.3695-3702
issn 1792-1074
1792-1082
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5431690
source PubMed Central
title Immunohistochemical analysis of NANOG expression and epithelial-mesenchymal transition in pulmonary sarcomatoid carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A02%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunohistochemical%20analysis%20of%20NANOG%20expression%20and%20epithelial-mesenchymal%20transition%20in%20pulmonary%20sarcomatoid%20carcinoma&rft.jtitle=Oncology%20letters&rft.au=Tamaki,%20Takeshi&rft.date=2017-05-01&rft.volume=13&rft.issue=5&rft.spage=3695&rft.epage=3702&rft.pages=3695-3702&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2017.5864&rft_dat=%3Cproquest_pubme%3E1901310901%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c450t-1bd817da55caf8fd566b47aee69d8c88a8af4b2467b0d6102bf6667439675ff53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1901310901&rft_id=info:pmid/28529586&rfr_iscdi=true